NEW JERSEY DRUG UTILIZATION REVIEW BOARD
QUAKERBRIDGE PLAZA, BUILDING 7, Rooms 200 ABC

January 13, 2016

http://www.state.nj.us/humanservices/dmahs/boards/durb/

AGENDA

I. Call to order in accordance with New Jersey Open Public Meeting Act

II. Roll Call

III. Review of draft meeting summary for October 14, 2015 meeting

IV. Secretary’s report

V. Old Business
   A. HMO responses to DURB follow-up questions
   B. Proposed protocol: Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) inhibitors

VI. New Business
   A. Protocol review:
      1. Proton pump inhibitors (PPIs)
      2. Oxycodone Controlled Release (Oxycontin®)

VII. Informational Highlights/Reports
   2. Summary of DURB Action Items
   3. DHS and DHSS Programs Top Drugs Report (by amount paid and by category)
   4. Medication information:
      (a) New FDA Drug Safety Communication on Viekira Pak® and Technivie®
      (b) FDA approves rare bleeding disorder therapy
      (c) CDC Finds Nursing Home Residents Wrongly Prescribed Antibiotics Up To 75 Percent Of The Time
      (d) FDA Approves Drug To Reverse Effect Of Anticoagulant